ArticleJournal of the National Cancer Institute2021
Annual Report to the Nation on the Status of Cancer, Part 1: National Cancer Statistics.
Article in Journal of the National Cancer Institute, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05234177 (Tempus CRC Surveillance Study), which is not on this map. Cited by 258 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Tempus CRC Surveillance Study: A Longitudinal Circulating Tumor DNA (ctDNA) Biomarker Profiling Study of Patients With Colorectal Cancer (CRC) Using Comprehensive Next-Generation Sequencing (NGS)Assays
Who cites it
258 citing papers in PubMed, 5 syntheses or guidelines pooled it, 482 citations in OpenAlex.
- Utility of CA-125 for diagnosis and prognosis of breast cancer: a systematic review.Exploration of targeted anti-tumor therapy · 2025Pooled it
- A Systematic Review of Interpersonal Interactions Related to Racism in Studies Assessing Breast and Gynecological Cancer Health Outcomes Among Black Women.Journal of racial and ethnic health disparities · 2024Pooled it
- Impact of metformin on melanoma: a meta-analysis and systematic review.Frontiers in oncology · 2024Pooled it
- Physicians' attitudes and experiences about withholding/withdrawing life-sustaining treatments in pediatrics: a systematic review of quantitative evidence.BMC palliative care · 2023Pooled it
- Light at night exposure and risk of breast cancer: a meta-analysis of observational studies.Frontiers in public health · 2023Pooled it
- Efficacy of an Educational Health Intervention for Oral Cancer Aimed at Dentists and Dental Students.Journal of cancer education : the official journal of the American Association for Cancer Education · 2026Trial
- Overall Survival and Exploratory Biomarker Analyses of Abemaciclib plus Trastuzumab with or without Fulvestrant versus Trastuzumab plus Chemotherapy in HR+, HER2+ Metastatic Breast Cancer Patients.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Trial
- Trial
- Clinical implementation of automated IMRT/VMAT planning for lung cancer radiation therapy using the expedited constrained hierarchical optimization (ECHO) system.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026Article
- Type 2 Diabetes Risk Among Older Asian, Native Hawaiian and Pacific Islander Patients With Head and Neck Cancer in the United States.Cancer medicine · 2026Article
- Driving tumor-associated macrophages to a CXCL9Cell reports. Medicine · 2026Article
- Article
- Cancer-specific mortality of grade group 1 prostate cancer: Results from Surveillance, Epidemiology, and End Results Database, 2004-2021.Current urology · 2026Article
- Trends in mortality from cancer and sepsis in the United States, 1999 to 2023: An analysis of CDC WONDER data.Medicine · 2026Article
- TRIM29 is Critical for Bladder Cancer Progression and Modulates the Tumor-Immune Niche.Research square · 2026Article
- Azathioprine Toxicity in Patients With Myasthenia Gravis: A Single Center Experience.Muscle & nerve · 2026Article
- Vitamin D receptor isoform VDRA suppresses hepatocellular tumorigenesis by restricting YAP nuclear localization.Cell death & disease · 2026Article
- Construction of an efferocytosis related signature to predict the prognosis of pancreatic ductal adenocarcinoma.Discover oncology · 2026Article
- A nomogram model based on dual-center data predicts lymph node metastasis in endometrial cancer.Discover oncology · 2026Article
- Investigation of the relationship between helicobacter pylori positivity and colon polyps in simultaneous oesophagogastroduodenoscopy and colonoscopy procedures.Journal of minimal access surgery · 2026Article
198 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundThe American Cancer Society, Centers for Disease Control and Prevention, National Cancer Institute, and North American Association of Central Cancer Registries collaborate to provide annual updates on cancer incidence and mortality and trends by cancer type, sex, age group, and racial/ethnic group in the United States. In this report, we also examine trends in stage-specific survival for melanoma of the skin (melanoma).
methodsIncidence data for all cancers from 2001 through 2017 and survival data for melanoma cases diagnosed during 2001-2014 and followed-up through 2016 were obtained from the Centers for Disease Control and Prevention- and National Cancer Institute-funded population-based cancer registry programs compiled by the North American Association of Central Cancer Registries. Data on cancer deaths from 2001 to 2018 were obtained from the National Center for Health Statistics' National Vital Statistics System. Trends in age-standardized incidence and death rates and 2-year relative survival were estimated by joinpoint analysis, and trends in incidence and mortality were expressed as average annual percent change (AAPC) during the most recent 5 years (2013-2017 for incidence and 2014-2018 for mortality).
resultsOverall cancer incidence rates (per 100 000 population) for all ages during 2013-2017 were 487.4 among males and 422.4 among females. During this period, incidence rates remained stable among males but slightly increased in females (AAPC = 0.2%, 95% confidence interval [CI] = 0.1% to 0.2%). Overall cancer death rates (per 100 000 population) during 2014-2018 were 185.5 among males and 133.5 among females. During this period, overall death rates decreased in both males (AAPC = -2.2%, 95% CI = -2.5% to -1.9%) and females (AAPC = -1.7%, 95% CI = -2.1% to -1.4%); death rates decreased for 11 of the 19 most common cancers among males and for 14 of the 20 most common cancers among females, but increased for 5 cancers in each sex. During 2014-2018, the declines in death rates accelerated for lung cancer and melanoma, slowed down for colorectal and female breast cancers, and leveled off for prostate cancer. Among children younger than age 15 years and adolescents and young adults aged 15-39 years, cancer death rates continued to decrease in contrast to the increasing incidence rates. Two-year relative survival for distant-stage skin melanoma was stable for those diagnosed during 2001-2009 but increased by 3.1% (95% CI = 2.8% to 3.5%) per year for those diagnosed during 2009-2014, with comparable trends among males and females.
conclusionsCancer death rates in the United States continue to decline overall and for many cancer types, with the decline accelerated for lung cancer and melanoma. For several other major cancers, however, death rates continue to increase or previous declines in rates have slowed or ceased. Moreover, overall incidence rates continue to increase among females, children, and adolescents and young adults. These findings inform efforts related to prevention, early detection, and treatment and for broad and equitable implementation of effective interventions, especially among under resourced populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.